| KVUE |
Report |
Q2 2026 net sales |
IN-LINE |
pred ~$4.00B vs. cons $3.97B |
MEDIUM |
| KVUE |
Report |
Q2 2026 adjusted diluted EPS |
BEAT |
pred ~$0.33 vs. cons $0.32 |
MEDIUM |
| KVUE |
Report |
Q2 2026 organic sales growth |
BEAT |
pred ~1.2% vs. cons 0.8% |
LOW |
| KVUE |
Guide |
Kimberly-Clark transaction closing timing |
UNCHANGED |
guide ~2H 2026 vs. cons 2H 2026 (transaction closing period) |
HIGH |
| KVUE |
Guide |
Restructuring charges |
UNCHANGED |
guide ~$250M vs. cons $250M (FY2026) |
MEDIUM |
| KVUE |
Guide |
Annualized restructuring savings |
UNCHANGED |
guide ~$200M vs. cons $200M (run-rate upon completion) |
MEDIUM |
| KVUE |
Return |
Day-1 residual (stock − beta × S&P 500) |
+0.5% |
— |
LOW |
| KVUE |
Return |
5-day cumulative residual |
+0.3% (STABILIZE) |
A modest EPS and organic-sales beat should tighten the approximately 1.4% deal spread initially, but absent financial guidance or a more precise closing date there is little out-period estimate revision support; the cash-and-stock merger consideration and KMB price movements should re-anchor KVUE after the initial reaction. |
LOW |